Immutep Ltd (AU:IMM) has released an update.
Immutep Ltd reports promising initial results from their Phase II EFTISARC-NEO trial, which shows the company’s novel triple-combination therapy for soft tissue sarcoma to be well-tolerated and highly effective in initial patients. With four out of six patients exhibiting near-complete pathologic responses—a result seldom achieved with standard treatments—the therapy could represent a significant advancement for this hard-to-treat cancer with a high unmet medical need. Further data is expected to be presented in the second half of 2024, as more patients are enrolled in the ongoing trial.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.
